Work

Supplementary Figures S1-S5 from Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells

Year: 2023

Type: supplementary-materials

Abstract: MPC6 inhibits AR transcriptional activity (S1); MPC6 treatment did not decrease AR protein level in prostate cancer cell lines (S2); MPC6's anti-proliferative effect in non-prostate cancer cell lines (S3); PK/PD analysis for plasma MPC6 concentration (S4); MPC6 treatment did not significantly reduce host body weight (S5).

DOI: 10.1158/0008-5472.22411320

Authors: Yu Wang, Dilani C. Dehigaspitiya, Paul M. Levine, Adam A. Profit, Michael Haugbro, Keren Imberg-Kazdan, Susan K. Logan, Kent Kirshenbaum, Michael J. Garabedian

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361973159

Cites:

Cited by:

Related to: 10